SuppTable 2b. Comparison of LCH Array Gene Expression to Previous Reports.  CD3+Array (LCH Lesion CD3+ vs LCH Peripheral CD3+) Langerhans cell histiocytosis (LCH) is a rare disease characterized by heterogeneous lesions containing CD207+ Langerhans cells (LCs) and lymphocytes that can arise in almost any tissue and cause significant morbidity and mortality. After decades of research, the cause of LCH remains speculative. Results from this study support a model of LCH pathogenesis in which lesions do not arise from epidermal LCs but from accumulation of bone marrow-derived immature myeloid dendritic cells that recruit activated lymphocytes.

SuppTable 3. LCH Lesion CD3 vs Control Tonsil CD3 Array Results (L-CD3/Tonsil-CD3) Langerhans cell histiocytosis (LCH) is a rare disease characterized by heterogeneous lesions containing CD207+ Langerhans cells (LCs) and lymphocytes that can arise in almost any tissue and cause significant morbidity and mortality. After decades of research, the cause of LCH remains speculative. Results from this study support a model of LCH pathogenesis in which lesions do not arise from epidermal LCs but from accumulation of bone marrow-derived immature myeloid dendritic cells that recruit activated lymphocytes.

Table 1 miR regulated during RA-induced neuroblastoma differentiation  a model of neuroblastoma differentiation  cortical development and embryonic stem cells differentiation  and control neurite outgrowth in vitro.

Table A2. Up- and Downregulated Probe Sets and Genes Identified in AML(acute myeloid leukemia)-Like Signature Versus NonAML-Like Signature of JMML (Juvenile myelomonocytic leukemia) Specimens

SuppTable 4. Genes implicated in breast cancer or immune response and present in the HDPP gene signature.

Table 2. Eighty-eight genes composing the progression-free survival-related profile.

Table 1. Statistically significant genes as prognostic markers and their diagnostic accuracy measured with the area under the ROC curve and the associated p values